Skip to main content
. Author manuscript; available in PMC: 2015 May 21.
Published in final edited form as: Phys Med Biol. 2014 Apr 28;59(10):2535–2547. doi: 10.1088/0031-9155/59/10/2535

Table 1.

Patient characteristics by normal tissue complication status.

Necrosis: No Necrosis: Yes p-value
n 22 7
Female 11 (50%) 4 (57%) 0.75
Median age; range (years) 62; 22–78 44; 31–75 0.27
Median prescription dose to PTV2; fraction (Gy) 75; 2.5 78; 2.6 0.05
Median whole brain gEUD (range) (Gy) 68.1 (55.4–74.1) 72.5 (64.8–75.8) 0.04
Received bevacizumab 6 (27.2%) 1 (14.3%) 0.65
Frontal tumor 2 (9.1%) 2 (28.6%) 0.30
Occipital tumor 2 (9.1%) 2 (28.6%) 0.30
Parietal tumor 5 (22.7%) 1 (14.3%) 0.61
Temporal tumor 13 (59.1%) 2 (28.6%) 0.16
3T MRI scanner 14 (63.3%) 3 (42.9%) 0.36
Mean splenium gEUD Gy (SE) 49.3 (4.8) 63.8 (5.7) 0.13
10-Gy splenium dose-volume % (SE) 84.1 (5.5) 99.0 (0.4) 0.10
20-Gy splenium dose-volume % (SE) 66.1 (7.9) 84.7 (3.5) 0.14
30-Gy splenium dose-volume % (SE) 57.6 (8.2) 69.4 (5.6) 0.26
40-Gy splenium dose-volume % (SE) 47.3 (7.7) 58.7 (6.6) 0.26
50-Gy splenium dose-volume % (SE) 38.8 (7.3) 47.8 (7.5) 0.30
60-Gy splenium dose-volume % (SE) 26.3 (6.6) 38.1 (8.3) 0.24

SE: standard error.